Status:
COMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.
Lead Sponsor:
Takeda
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma receptor after 6 months...
Detailed Description
The metabolic control in type 2 diabetes mellitus can be measured by means of glycosylated hemoglobin. A low value glycosylated hemoglobin indicates a good metabolic control, and has been shown to be ...
Eligibility Criteria
Inclusion
- Fulfills all requirements for treatment with pioglitazone.
- Willing to start treatment with pioglitazone.
Exclusion
- Has previously participated in this study.
- Is currently taking or have taken oral antidiabetic medications other than sulfonylurea or metformin within the last 30 days.
Key Trial Info
Start Date :
June 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2003
Estimated Enrollment :
326 Patients enrolled
Trial Details
Trial ID
NCT00449553
Start Date
June 1 2001
End Date
September 1 2003
Last Update
February 28 2012
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple, Denmark
2
Multiple, Iceland
3
Multiple, Norway
4
Multiple, Sweden